Posted by Michael Wonder on 09 Aug 2021
Skyrizi (risankizumab-rzaa) now available in the U.S. as a single 150 mg injection for adults with moderate to severe plaque psoriasis
9 August 2021 - Skyrizi is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or pre-filled syringe.
AbbVie today announced that Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, is now available in the U.S. as a single-dose 150 mg injection for the treatment of adults with moderate to severe plaque psoriasis.
Previously two 75 mg injections per dose, Skyrizi 150 mg is now administered with one injection per dose – via either a pre-filled pen or syringe – every 12 weeks following two starter doses.
